Avedro Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 122

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $438M

Avedro General Information

Description

Avedro Inc is a commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Its Avedro Corneal Remodeling Platform is designed to strengthen, stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions. The company geographically operates through United States, Asia, Europe, Americas (outside the United States), Middle East and Other locations.

Contact Information

Website
www.avedro.com
Formerly Known As
ThermalVision
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 201 Jones Road
  • Waltham, MA 02451
  • United States
+1 (781)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Acquirer
Glaukos
Vertical(s)
TMT, HealthTech, Life Sciences
Corporate Office
  • 201 Jones Road
  • Waltham, MA 02451
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avedro Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 21-Nov-2019 $438M Completed Profitable
10. IPO 14-Feb-2019 Completed Profitable
9. Later Stage VC (Series CC) 26-Apr-2018 Completed Profitable
8. Later Stage VC (Series BB) 27-Apr-2017 Completed Profitable
7. Later Stage VC (Series AA) 13-Nov-2015 Completed Profitable
6. Later Stage VC (Series D) 05-Nov-2014 Completed Profitable
5. Later Stage VC (Series D) 05-Mar-2013 Completed Profitable
4. Later Stage VC (Series C) 17-Feb-2012 Completed Profitable
3. Later Stage VC (Series B) 08-May-2009 $10M $19.6M Completed Profitable
2. Later Stage VC (Series A1) 29-Jan-2008 $8M $9.6M Completed Profitable
To view Avedro’s complete valuation and funding history, request access »

Avedro Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series CC
Series BB
Series AA 32,650,000 $0.08 $1 $1 1x $1 48.95%
To view Avedro’s complete cap table history, request access »

Avedro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Avedro Inc is a commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and
Pharmaceuticals
Waltham, MA
122 As of 2018

Alpharetta, GA
 

Sao Paulo, Brazil
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Avedro Competitors (3)

One of Avedro’s 3 competitors is Clearside Biomedical, a Formerly VC-backed company based in Alpharetta, GA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Clearside Biomedical Formerly VC-backed Alpharetta, GA
Bausch+Lomb Brasil Corporation Sao Paulo, Brazil
Opus Genetics Formerly VC-backed Durham, NC
You’re viewing 3 of 3 competitors. Get the full list »

Avedro Patents

  • 413

    Total Documents Applications and Grants

  • Total Patents Families

  • 219

    Granted

  • 76

    Pending

  • Expiring in next 12 mo

Avedro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250166188-A1 Systems and methods for generating patient-specific corneal cross- linking treatment patterns Pending 08-Mar-2021
AU-2022232309-A1 Systems and methods for generating patient-specific corneal cross-linking treatment patterns Pending 08-Mar-2021
CA-3213111-A1 Systems and methods for generating patient-specific corneal cross-linking treatment patterns Pending 08-Mar-2021
EP-4304539-A1 Systems and methods for generating patient-specific corneal cross-linking treatment patterns Pending 08-Mar-2021
US-12293513-B2 Systems and methods for generating patient-specific corneal cross-linking treatment patterns Active 08-Mar-2021 G06T7/0012
To view Avedro’s complete patent history, request access »

Avedro Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avedro Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abingworth Venture Capital Minority
Aperture Venture Partners Venture Capital Minority
Borealis Ventures Venture Capital Minority
De Novo Ventures Venture Capital Minority
Echelon Ventures Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Avedro Acquisitions (1)

Avedro’s most recent deal was a Merger/Acquisition with IROC Innocross. The deal was made on 03-Sep-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
IROC Innocross 03-Sep-2014 Merger/Acquisition Diagnostic Equipment
To view Avedro’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Avedro FAQs

  • When was Avedro founded?

    Avedro was founded in 2002.

  • Where is Avedro headquartered?

    Avedro is headquartered in Waltham, MA.

  • What is the size of Avedro?

    Avedro has 122 total employees.

  • What industry is Avedro in?

    Avedro’s primary industry is Pharmaceuticals.

  • Is Avedro a private or public company?

    Avedro is a Private company.

  • What is the current valuation of Avedro?

    The current valuation of Avedro is .

  • What is Avedro’s current revenue?

    The current revenue for Avedro is .

  • How much funding has Avedro raised over time?

    Avedro has raised $297M.

  • Who are Avedro’s investors?

    Abingworth, Aperture Venture Partners, Borealis Ventures, De Novo Ventures, and Echelon Ventures are 5 of 17 investors who have invested in Avedro.

  • Who are Avedro’s competitors?

    Clearside Biomedical, Bausch+Lomb Brasil, and Opus Genetics are competitors of Avedro.

  • When was Avedro acquired?

    Avedro was acquired on 21-Nov-2019.

  • Who acquired Avedro?

    Avedro was acquired by Glaukos.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process